GYREGyre Therapeutics, Inc.
Since it joined the list
$GYRE landed on the list 2026-03-09, down 40.7% from its 52-week high that day — now $5.74.
That's 13.6 percentage points deeper than the day it joined. It bottomed 59.6% below that high along the way.
Decline from the 52-week high as it stood on 2026-03-09 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.
Structural break signals
GYRE qualifies for the Amber List on decline sigma.
The structural read
What price action says about GYRE.
GYRE qualifies for the Amber List on decline sigma — the recent drop measures 7.2σ over a 20-bar window. Sigma scales the move by the stock's own typical daily volatility, so a small percentage drop in a normally-quiet name can land here when the bigger players miss it on a pure-percent threshold.
52-week range
Questions about GYRE
What people ask.
Why is GYRE on Broken Stocks?
GYRE qualifies for the Amber List on decline sigma. The recent drop measures 7.2σ over a 20-bar window — large enough that even a small percentage drop is structurally significant given the stock's typical day-to-day volatility (4.15%).
Is GYRE a falling knife?
GYRE is on Broken Stocks for time-frame continuity or decline-sigma reasons rather than headline depth, so the falling-knife label doesn't cleanly apply. The phrase usually requires a meaningful percentage drop from a fresh high. See the structural break signals above for the axis that actually triggered the listing.
Is GYRE a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is GYRE trading inside its 52-week range?
At $5.74, GYRE sits 2.0% of the way from its 52-week low ($5.67) to its 52-week high ($9.14). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.